Dr. Desai discusses the heterogeneity of AML and why it's so important to have a clear understanding of a patient's genetic profile and risks.
Published on November 5, 2018 in Treatment
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Published on October 18, 2018 in Treatment
Dr. Cortes discusses what to look for when managing patients being treated with an IDH1 or IDH2 inhibitor.
Published on September 24, 2018 in Treatment
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.
Published on September 20, 2018 in Treatment
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
Published on July 3, 2018 in Treatment
Dr. Daver summarizes the four drug approvals for AML in 2017 and how you should be using these treatments in various patient populations.
Published on June 13, 2018 in Treatment
Dr. Daver reviews targeted therapies under investigation, recently approved, and near approval in the treatment of AML.
Published on June 6, 2018 in Treatment
Dr. Carraway discusses the difference between the median time to response and the median time to best response with enasidenib, and how to properly monitor patients on this drug.
Published on May 23, 2018 in Treatment
Dr. Daver discusses the best options, both in current standard of care as well as under investigation, for treating patients unfit for intensive chemotherapy (generally patients above the age of 65).
Published on May 9, 2018 in Treatment
Dr. Lancet explains what we know - and don't know - about therapy-related AML: its causes, features, treatment options, and prognosis.
Published on February 28, 2018 in Treatment